Cargando…

Initial experience with minimally invasive treatment of pilonidal sinus in children

INTRODUCTION: Sinus pilonidalis (SP) is an acquired inflammatory disease, which is relatively common in the paediatric population. Surgery is indicated in symptomatic patients. In 2017, minimally invasive pilonidal sinus treatment (EPSiT) was adapted to the paediatric population. AIM: To evaluate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Dotlacil, Vojtech, Rygl, Michal, Frybova, Barbora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193749/
https://www.ncbi.nlm.nih.gov/pubmed/34136040
http://dx.doi.org/10.5114/wiitm.2020.100714
Descripción
Sumario:INTRODUCTION: Sinus pilonidalis (SP) is an acquired inflammatory disease, which is relatively common in the paediatric population. Surgery is indicated in symptomatic patients. In 2017, minimally invasive pilonidal sinus treatment (EPSiT) was adapted to the paediatric population. AIM: To evaluate the first experience with minimally invasive endoscopic treatment of SP (PEPSiT) in children and adolescents in the Czech Republic. MATERIAL AND METHODS: A retrospective review of all consecutive paediatric patients who underwent PEPSiT from November 2018 to February 2020. The monitored parameters were demographics, perioperative course of the disease, surgery, length of hospitalisation, postoperative complications, healing, disease recurrence, and follow-up. RESULTS: Seventeen patients were enrolled in the study. The median age at surgery was 17.1 years (range: 12.5–18). The subjects comprised 76% males, and the median body mass index was 25.6 kg/m(2) (range: 17–30.3 kg/m(2)). Thirteen patients underwent previous surgical treatment (76%) under local anaesthesia. The median duration of PEPSiT was 50 min (range: 30–85 min). The subjective evaluation of pain by patients on the VAS scale was 0 on the day of discharge. There were no postoperative complications up to the 30(th) postoperative day. Two disease recurrences were successfully managed by re-PEPSiT. By the end of follow-up, 14/15 patients had healed. Two patients are still within 3 months of surgery, which is too soon to definitively evaluate possible recurrence of the disease. CONCLUSIONS: These preliminary results show that PEPSiT is a highly promising method. It is safe and well-tolerated by patients (short hospital stay, quick return to normal life, low pain and analgesic consumption). Two recurrences of disease were treated by re-PEPSiT.